Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05371145 · ClinicalTrials.gov registry record · Phase 1
Carnosine for Peripheral Arterial Disease Patients
A Phase 1 study of Peripheral Arterial Disease, sponsored by Shahid Baba.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05371145 is a Phase 1 study of Peripheral Arterial Disease that is actively recruiting participants, run by Shahid Baba. The registered enrollment target is 20 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05371145, a Phase 1 study of Peripheral Arterial Disease, is actively recruiting participants, sponsored by Shahid Baba.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.
Conditions Studied
Interventions
- BIOLOGICAL Carnosine
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05371145
The ClinicalTrials.gov registry entry for NCT05371145 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The listed sponsor is Shahid Baba, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Carnosine is the first listed.
NCT05371145 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT05371145 about?
NCT05371145 is a clinical study titled "Carnosine for Peripheral Arterial Disease Patients". Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.
What is the current status of trial NCT05371145?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-03-01. Estimated completion is 2024-12-30.
What conditions does trial NCT05371145 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT05371145?
The interventions under investigation include: Carnosine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05371145?
This trial is sponsored by Shahid Baba, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05371145 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
RECRUITING · Phase 1
-
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
ACTIVE NOT RECRUITING · Phase 1
-
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
COMPLETED · Phase 1
-
Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)
COMPLETED · Phase 1
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
ALD-301 for Critical Limb Ischemia, Randomized Trial
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.